The Lighthouse Project is Moving into Large Phase 3 Clinical Trial
The Lighthouse Project will soon move into a large Phase 3 clinical trial. The project is investigating whether the HIV drug Triumeq is effective in treating people with MND. This project was partly funded through the MND Research Institute of Australia which includes research funding from MND Victoria.
Professor Julian Gold (photo right) and his team are investigating whether human endogenous retroviruses (HERVs) may play a role in motor neurone disease (MND) and whether targeting HERVs might provide a novel therapeutic avenue. This was the first Phase 2 clinical trial in the world to use modern combination anti-retroviral therapy in patients with MND.
The summary results show that Triumeq appears to be safe and well tolerated in patients with MND. It has considerable administration advantages as a single once-daily tablet which can be taken either whole or crushed.
Moreover, it is already licensed for HIV treatment and is available in most countries.
Initial results indicate Triumeq may have a biological effect both clinically and on biomarkers in patients with ALS, and all effects appear to be positive.
However, this was only a small study and a much larger international multicentre phase 3 placebo-controlled trial is now planned to determine if Triumeq improves both survival and clinical progression. This definitive trial will be conducted in Europe, the UK and at five sites in Australia. It is hoped this trial will begin early in 2020.
For further information about the Phase 3 trial and recruitment, please discuss with your neurologist. Further infomation about the project is available on the MND Australia website: http://www.mndaust.asn.au/Discover-our-research/Latest-research/Clinical-trials/The-Lighthouse-Project
Read more MND news: